Search Results - "Limdi, N."

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update by Johnson, JA, Caudle, KE, Gong, L, Whirl‐Carrillo, M, Stein, CM, Scott, SA, Lee, MT, Gage, BF, Kimmel, SE, Perera, MA, Anderson, JL, Pirmohamed, M, Klein, TE, Limdi, NA, Cavallari, LH, Wadelius, M

“…This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin…”
Get full text

Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African‐American and European‐American Patients on Warfarin by Limdi, NA, McGwin, G, Goldstein, JA, Beasley, TM, Arnett, DK, Adler, BK, Baird, MF, Acton, RT

“…The association of CYP2C9 and VKORC1 1173C/T genotype and risk of hemorrhage among African Americans and European Americans is presented. This association was…”
Get full text

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data by Klein, T E, Altman, R B, Eriksson, N, Gage, B F, Kimmel, S E, Lee, M-T M, Limdi, N A, Page, D, Roden, D M, Wagner, M J, Caldwell, M D, Johnson, J A

“…There is substantial variation in the dose of warfarin required to achieve therapeutic anticoagulation. In this study, mathematical models for warfarin dosage…”
Get full text

Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update by Haaz, S., Fontaine, K. R., Cutter, G., Limdi, N., Perumean-Chaney, S., Allison, D. B.

“…Summary Obesity is a major health problem facing the developed and developing world. Efforts by individuals, health professionals, educators, and policy makers…”
Get full text

Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype‐Guided Antiplatelet Therapy by Harada, S, Zhou, Y, Duncan, S, Armstead, AR, Coshatt, GM, Dillon, C, Brott, BC, Willig, J, Alsip, JA, Hillegass, WB, Limdi, NA

“…Precision medicine entails tailoring treatment based on patients' unique characteristics. As drug therapy constitutes the cornerstone of treatment for most…”
Get full text

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting by Cavallari, LH, Beitelshees, AL, Blake, KV, Dressler, LG, Duarte, JD, Elsey, A, Eichmeyer, JN, Empey, PE, Franciosi, JP, Hicks, JK, Holmes, AM, Jeng, LJB, Lee, CR, Lima, JJ, Limdi, NA, Modlin, J, Obeng, AO, Petry, N, Pratt, VM, Skaar, TC, Tuteja, S, Voora, D, Wagner, M, Weitzel, KW, Wilke, RA, Peterson, JF, Johnson, JA

“…Following establishment of the IGNITE Network in 2013, the Pharmacogenetics Working Group was formed in January 2015 with the goals of broadly engaging…”
Get full text

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing by Lenzini, P, Wadelius, M, Kimmel, S, Anderson, J L, Jorgensen, A L, Pirmohamed, M, Caldwell, M D, Limdi, N, Burmester, J K, Dowd, M B, Angchaisuksiri, P, Bass, A R, Chen, J, Eriksson, N, Rane, A, Lindh, J D, Carlquist, J F, Horne, B D, Grice, G, Milligan, P E, Eby, C, Shin, J, Kim, H, Kurnik, D, Stein, C M, McMillin, G, Pendleton, R C, Berg, R L, Deloukas, P, Gage, B F

“…Well‐characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9) and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain…”
Get full text

Efficacy of rapid IV administration of valproic acid for status epilepticus by LIMDI, N. A, SHIMPI, A. V, FAUGHT, E, GOMEZ, C. R, BURNEO, J. G

“…Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this…”
Get full text

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy by Limdi, N.A., Wiener, H., Goldstein, J.A., Acton, R.T., Beasley, T.M.

“…Although multiple reports have documented the influence of CYP2C9 and VKORC1 variants on warfarin dose, risk of over-anticoagulation and hemorrhage, their…”
Get full text

Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy by Dutta, S., Faught, E., Limdi, N. A.

“…To characterize protein binding in patients with epilepsy who achieve transient high (>150 mg/L) total plasma concentrations following rapid valproate infusion…”
Get full text

A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy by Goldstein, J.A., Blaisdell, J.A., Limdi, N.A.

“…Possession of a variant Cytochrome P450 2C9 (CYP2C9) genotype has been associated with a higher risk of hemorrhagic complications among warfarin users. [ 1 ; 2…”
Get full text

The Safety of Rapid Valproic Acid Infusion by Limdi, Nita A., Faught, Edward

“…Summary Purpose: The recommended rate of administration of valproic acid injection is 20 mg/min. Drug delivery at this rate may be inadequate for expeditious…”
Get full text

Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy by Limdi, N.A., Beasley, T.M., Allison, D.B., Rivers, C.A., Acton, R.T.

“…We report the prevalence of Factor V Leiden (FVL) in European American and African American patients on warfarin therapy residing in Alabama. Detailed history…”
Get full text

Neurotoxicity following addition of intravenous valproate to lamotrigine therapy by BURNEO, J. G, LIMDI, N, KUZNIECKY, R. I, KNOWLTON, R. C, MENDEZ, M, LAWN, N, FAUGHT, E, WELTY, T. E, PRASAD, A

“…Reversible neurotoxic symptoms were observed in three adult patients with absence status epilepticus on lamotrigine (LTG) therapy after administration of an IV…”
Get full text

263 Pharmacogenomics in people with cystic fibrosis: A personalized medicine approach by Anderson, J., Brittney, D., Giang, G., Smith, A., Lee, C., Parker, K., Searcy, H., Benner, K., Limdi, N., Guimbellot, J.

Get full text

Prediction of intra ocular lens power in 100 patients using the ophthasonic a scan unit by Limdi, N K, Sheth, K J

“…The aim of this study was to determine the range of ametropias encountered by using the computerized Ophthasonic A-Scan. The SRK formula was used to compute…”
Get full text

Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations: Finding Signal within the Noise by Gamazon, E. R., Daneshjou, R., Cavallari, L. H., Limdi, N. A., Wadelius, Mia, Johnson, J. A., Klein, T. E., Scott, S., Tsunoda, T., Deloukas, P., Altman, R., Cox, N., Perera, M. A.

Get full text

Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy1 by Dutta, S., Faught, E., Limdi, N. A.

“…Summary Objective:  To characterize protein binding in patients with epilepsy who achieve transient high (>150 mg/L) total plasma concentrations following…”
Get full text

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

“…Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data Original Article, N Engl J Med 2009:360;753-764.. In Table 2 (page 758), the mean…”
Get full text

Warfarin Pharmacogenetics by Limdi, Nita A., Veenstra, David L.

“…Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of…”
Get full text